Praxis Precision Medicines Files 8-K

Ticker: PRAX · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1689548

Praxis Precision Medicines, Inc. 8-K Filing Summary
FieldDetail
CompanyPraxis Precision Medicines, Inc. (PRAX)
Form Type8-K
Filed DateOct 16, 2025
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, pharmaceutical

TL;DR

Praxis Precision Medicines dropped an 8-K on 10/16/25 - check it for updates.

AI Summary

Praxis Precision Medicines, Inc. filed an 8-K on October 16, 2025, reporting on events that occurred on the same date. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, incorporated in Delaware, is based in Boston, MA, and operates in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing indicates that Praxis Precision Medicines is making disclosures to the SEC regarding significant events or financial information, which could impact investor understanding of the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain any immediately alarming or negative information.

Key Players & Entities

  • Praxis Precision Medicines, Inc. (company) — Registrant
  • October 16, 2025 (date) — Date of earliest event reported
  • Boston, Massachusetts (location) — Principal executive offices
  • Delaware (location) — State of incorporation

FAQ

What specific events are being disclosed under Regulation FD?

The filing does not specify the exact events covered under Regulation FD Disclosure in the provided text.

Are there any significant financial statements or exhibits attached to this 8-K?

The filing indicates that 'Financial Statements and Exhibits' are included, but the specific content is not detailed in the provided text.

What is the primary business of Praxis Precision Medicines, Inc.?

Praxis Precision Medicines, Inc. operates in the Pharmaceutical Preparations industry, with SIC code 2834.

When was Praxis Precision Medicines, Inc. incorporated?

The company was incorporated in Delaware.

What is the mailing address and phone number for Praxis Precision Medicines, Inc.?

The mailing address is 99 High Street, 30th Floor, Boston, MA 02110, and the telephone number is (617) 300-8460.

Filing Stats: 1,563 words · 6 min read · ~5 pages · Grade level 10.1 · Accepted 2025-10-16 07:58:26

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq Glo

Filing Documents

01. Other Events

Item 8.01. Other Events. On October 16, 2025, the Company announced positive topline results for the Phase 3 Essential3 program of ulixacaltamide in essential tremor ("ET"). About the Essential3 Program Trial Design The Essential3 Phase 3 program (NCT06087276) included two simultaneously enrolled studies utilizing a decentralized design conducted within the United States, where participants were allocated to the studies in a 2:1 blinded randomization (Study 1:Study 2). Study 1 was a double-blind, parallel design, placebo-controlled study that enrolled 473 patients randomized 1:1 to receive either ulixacaltamide or placebo for 12 weeks. The primary endpoint was the change from baseline in mADL11 at Week 8. Study 2 was a stable-responder randomized withdrawal study that enrolled 238 patients to receive ulixacaltamide for 8 weeks. Patients who improved by 3 points in the mADL11 from baseline were then randomized to receive either placebo or to continue receiving ulixacaltamide for an additional 4 weeks. The primary endpoint evaluated the proportion of patients who maintained response receiving ulixacaltamide versus placebo. There were two additional pre-specified hypotheses evaluating combinations of arms in Study 1 and Study 2 using the change in mADL11 at Week 8. Hypothesis 3 compared the ulixacaltamide arms of Study 1 and Study 2 with the placebo arm of Study 1, and Hypothesis 4 compared the ulixacaltamide arm of Study 2 with the placebo arm of Study 1. Key secondary endpoints in Studies 1 and 2 assessed the rate of disease improvement (slope of mADL11 change), the Patient Global Impression of change ("PGI-C") and Clinical Global Impression of severity ("CGI-S"). Summary of Essential3 Program Results Study 1: Placebo-controlled Parallel Group Study Topline Efficacy Results In Study 1, there was a statistically significant and clinically meaningful 4.3 point mean improvement in the mADL11 score at Week 8 (p<0.0001). The effect was sustained from Week 2 thro

Forward-Looking Statements

Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the clinical development of ulixacaltamide and the anticipated timing of regulatory submissions and interactions. The forward-looking statements included in this Current Report are subject to a number of risks, uncertainties and assumptions, including, without limitation, uncertainties inherent in clinical trials, the expected timing of submission for regulatory approval or review by governmental authorities and other risks as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and its other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 E ssential 3 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRAXIS PRECISION MEDICINES, INC. Date: October 16, 2025 By: /s/ Marcio Souza Marcio Souza Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.